BioCentury | Apr 2, 2019
Distillery Therapeutics

Conbriza bazedoxifene for MS and other demyelinating diseases

...as one of six possible targets involved in promoting OPC differentiation. Next steps include testing Duavee...
...Almirall S.A. and Ligand Pharmaceuticals Inc. market Conbriza for postmenopausal osteoporosis. Pfizer and Ligand market Duavee...
...Riley Bove, same affiliation as above email: Riley.Bove@ucsf.edu Mark Zipkin Conbriza, Viviant, bazedoxifene Duavee, Duavive, conjugated estrogens/bazedoxifene (ce/bza) (Aprela, bazedoxifene CE, bazedoxifene/conjugated estrogens (BZA/CE)) University...
BioCentury | Feb 2, 2015
Clinical News

Duavive conjugated estrogens/bazedoxifene regulatory update

...The European Commission approved Duavive conjugated estrogens/bazedoxifene from Pfizer to treat estrogen deficiency symptoms in postmenopausal...
...uterus for whom progestin-containing therapy is inappropriate. Pfizer markets the drug in the U.S. as Duavee...
...NASDAQ:LGND), La Jolla, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Duavive conjugated estrogens/bazedoxifene ( Duavee...
BioCentury | Nov 10, 2014
Clinical News

Duavive conjugated estrogens/bazedoxifene regulatory update

...EMA's CHMP recommended approval of Duavive conjugated estrogens/bazedoxifene from Pfizer to treat estrogen deficiency in postmenopausal...
...deficiency in postmenopausal women for whom progestin-containing therapy is inappropriate. FDA approved the drug as Duavee...
...Inc. (NASDAQ:LGND), La Jolla, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Duavive conjugated estrogens/bazedoxifene (CE/BZA) ( Duavee...
BioCentury | Nov 18, 2013
Analyst Picks & Changes

Analyst picks & changes

...her revenue forecasts are still below Ligand's guidance due to her modest expectations for Duavee conjugated estrogens/bazedoxifene (CE/BZA)...
BioCentury | Oct 14, 2013
Clinical News

Duavee conjugated estrogens/bazedoxifene regulatory update

...Pfizer and partner Ligand said FDA approved an NDA for 0.45 mg/20 mg Duavee conjugated estrogens/bazedoxifene (CE/BZA) to...
...to prevent postmenopausal osteoporosis. FDA also issued a complete response letter for 0.625 mg/20 mg Duavee...
...Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Duavee conjugated estrogens/bazedoxifene (CE/BZA)...
BioCentury | Jul 1, 2013
Finance

3Q Financial Markets Preview: Punctuated equilibrium

...ATX-101) Reduce submental (under chin) fat Submit MAA 2H13 Ligand Pharmaceuticals Inc. (NASDAQ:LGND)/Pfizer Inc. (NYSE:PFE) Bazedoxifene/conjugated estrogens (BZA/CE)...
BioCentury | Dec 24, 2012
Clinical News

Bazedoxifene/conjugated estrogens regulatory update

...Ligand and Pfizer said FDA accepted for review an NDA for bazedoxifene/conjugated estrogens (BZA/CE) to treat non-hysterectomized women...
...osteoporosis. Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Bazedoxifene/conjugated estrogens (BZA/CE)...
BioCentury | Jul 23, 2012
Clinical News

Bazedoxifene/conjugated estrogens regulatory update

...Pfizer said EMA accepted for review an MAA for bazedoxifene/conjugated estrogens (BZA/CE) to treat symptoms associated with menopause...
...osteoporosis. Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Bazedoxifene/conjugated estrogens (BZA/CE)...
BioCentury | Sep 26, 2011
Clinical News

Bazedoxifene/conjugated estrogens: Phase III data

...III SMART-5 trial in 1,843 non-hysterectomized, postmenopausal women showed that once-daily low- and high-dose oral bazedoxifene/conjugated estrogens (BZA/CE)...
BioCentury | Aug 31, 2009
Strategy

Ligand pipeline

...PS291822) - asthma, chronic obstructive pulmonary disease (COPD) (A) Wyeth (NYSE:WYE), being acquired by Pfizer Aprela...
Items per page:
1 - 10 of 19